Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Proceedings of the National Academy of Sciences of the United States of America"
DOI: 10.1073/pnas.2206824119
Abstract: Significance Resistance to targeted and immunotherapeutic agents has emerged as a critical impediment to melanoma therapy. This study identifies the bromosporine/cobimetinib combination as a therapeutic strategy with broad-based activity in multiple settings, including in both… read more here.
Keywords: bromodomain inhibition; melanoma; inhibition overcomes; resistance ... See more keywords
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Sign Up to like & getrecommendations! Published in 2019 at "Journal for Immunotherapy of Cancer"
DOI: 10.1186/s40425-019-0758-y
Abstract: BackgroundProstate cancer responds poorly to current immunotherapies. Epigenetic therapies such as BET Bromodomain inhibition can change the transcriptome of tumor cells, possibly making them more immunogenic and thus susceptible to immune targeting.MethodsWe characterized the effects… read more here.
Keywords: prostate cancer; bromodomain inhibition; inhibition; bet bromodomain ... See more keywords
CBP Bromodomain Inhibition Rescues Mice From Lethal Sepsis Through Blocking HMGB1-Mediated Inflammatory Responses
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2020.625542
Abstract: CREB binding protein (CBP), a transcriptional coactivator and acetyltransferase, is involved in the pathogenesis of inflammation-related diseases. High mobility group box-1 protein (HMGB1) is a critical mediator of lethal sepsis, which has prompted investigation for… read more here.
Keywords: hmgb1; cbp bromodomain; bromodomain inhibition; lethal sepsis ... See more keywords